TransMedics Group, Inc. (TMDX) 주식 분석

회사 개요

TransMedics Group, Inc. is a commercial-stage medical technology firm dedicated to transforming organ transplant therapy for patients suffering from end-stage organ failure in both the United States and international markets. The company operates within the healthcare sector, specifically focusing on the medical devices industry, where it provides the Organ Care System (OCS) to enable portable organ perfusion, optimization, and monitoring. As of the latest reporting period, the enterprise holds a market capitalization of $3.75B and reports annual revenue of $605.49M, employing a workforce of 898 individuals. These financial scales indicate that the company has achieved significant commercial traction and holds a substantial market position, evidenced by a market cap that reflects investor confidence in its growth potential while maintaining a revenue base that supports its operational expansion.

재무 건전성

The company reported revenue of $605.49M and net income of $190.29M for the trailing twelve months, with an EBITDA of $134.47M, revealing a cost structure where operating expenses and taxes consume approximately $415.20M of gross revenue before arriving at the bottom line. The firm generated free cash flow of $94.00M, which provides a robust buffer for financial flexibility, allowing the organization to fund research and development or return capital to shareholders without relying on external financing. Profitability metrics show a gross margin of 59.9%, indicating high efficiency in production and supply chain management, while an operating margin of 13.2% and a profit margin of 31.4% demonstrate strong control over overhead costs and effective tax management. The balance sheet shows a cash position of $488.37M against total debt of $519.28M, resulting in a debt-to-equity ratio of 109.76, which suggests the company utilizes a leveraged capital structure to finance its operations. Despite the leverage, the current ratio stands at 7.14, signaling exceptionally strong short-term liquidity and the ability to cover current liabilities with current assets many times over. Return on Equity is calculated at 54.2% and return on assets at 7.2%, metrics that reveal highly effective management in generating returns on shareholder equity relative to the asset base employed.

밸류에이션 평가

Valuation multiples indicate a trailing P/E ratio of 22.46 and a forward P/E of 29.69, where the higher forward multiple implies that the market expects earnings to grow significantly faster than the historical average over the coming year. The price-to-book ratio is 7.92, suggesting that the market values the company at a significant premium over its book value, likely due to the intangible value of its intellectual property and growth prospects. Alternative valuation metrics include a price-to-sales ratio of 6.20 and an EV/EBITDA of 28.13, which collectively suggest that investors are pricing in substantial future growth rather than current earnings power. Regarding price action, the stock has a 52-week high of $156.00 and a 52-week low of $66.85, trading well below the peak but reflecting the volatility inherent in high-growth biotech and medical device stocks. The beta value of 2.08 indicates that the stock's price volatility is more than double that of the broader market, meaning it tends to amplify market movements during periods of rising or falling investor sentiment.

Growth & Income

Growth metrics highlight a revenue growth rate of 32.2% year-over-year alongside an earnings growth rate of 1188.1% year-over-year, demonstrating that earnings are expanding at a pace vastly superior to revenue, which is characteristic of companies scaling operations or benefiting from margin expansion. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that management chooses to retain earnings for reinvestment into growth initiatives rather than distributing income to shareholders. This retention strategy is consistent with the high returns on equity and the need to fund capital-intensive medical device development and commercialization efforts. Overall, the growth and income profile is defined by aggressive expansion and capital reinvestment, supported by strong cash flow generation that sustains this high-growth trajectory without the need for external equity financing.